Leading Independent Proxy Advisory Firms ISS and Egan-Jones Recommend That MiMedx Shareholders Vote the BLUE Card FOR All Three of the Company s Director Nominees ISS Recommends Shareholders Vote AGAINST the Petit Group

Leading Independent Proxy Advisory Firms ISS and Egan-Jones Recommend That

MiMedx Shareholders Vote the BLUE Card FOR All Three of the Company s Director Nominees

ISS Recommends Shareholders Vote AGAINST the Petit Group s Shareholder Proposals

ISS Recommends Shareholders Do Not Vote the White Card

MARIETTA, Ga., June 11, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader in advanced

wound care and an emerging therapeutic biologics company, today announced that leading proxy advisory firms Institutional Shareholder Services ( ISS ) and Egan-Jones Proxy Services ( Egan-Jones ) have recommended MiMedx

shareholders vote FOR the Company s three director nominees K. Todd Newton, Dr. Kathleen Behrens Wilsey and Timothy R. Wright on the BLUE proxy card in connection with the Company s 2018 Annual Meeting

of Shareholders to be held on June 17, 2019.

To help sort through the many claims and counterclaims in a contested director election, institutional

investors such as mutual, pension and retirement funds rely on the recommendations from proxy advisory firms like ISS and Egan-Jones. These investors, who have investments in dozens, hundreds or even thousands of stocks, find it useful to hear the

perspectives of neutral, independent experts like ISS and Egan-Jones as they consider how to vote their shares.

In its report dated June 10, 2019,

ISS concluded the following1:

Additionally, ISS recommends shareholders vote AGAINST the two shareholder proposals submitted by Parker H.

Pete Petit on the BLUE card, advising for both:

In its report dated June 10, 2019, Egan-Jones concluded1:

Commenting on the ISS and Egan-Jones reports, Charles R. Evans, Chairman of the Board, stated, We are encouraged by ISS s and Egan-Jones s

strong support and their recommendations that MiMedx shareholders vote for all three of our highly qualified director nominees on the BLUE proxy card.

MiMedx urges shareholders to follow the ISS and Egan-Jones recommendations and vote FOR MiMedx s highly qualified nominees online or

by telephone, using the BLUE proxy card TODAY. Shareholders should be aware that a vote on Mr. Petit s white card even if you vote against Mr. Petit is not the same as voting for MiMedx s candidates. Please

Your Vote Is Important, No Matter How Many Or How Few Shares You Own.

If you have questions about how to vote your shares, or need additional assistance, please contact

the firm assisting MiMedx in the solicitation of proxies:

INNISFREE M&A INCORPORATED

Shareholders may call toll-free at 1 (877) 800-5195

Banks and Brokers may call collect at 1 (212) 750-5833

Sidley Austin LLP is acting as legal advisor to MiMedx.

MiMedx is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for

multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by

employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.5 million allografts to date. For additional information, please visit www.mimedx.com.

Corporate & Investor Communications

Joele Frank, Wilkinson Brimmer Katcher

Andy Brimmer / Jed Repko

/ Annabelle Rinehart